Recombinant adeno-associated virus vector related impurities

Shengwu Gongcheng Xuebao/Chinese Journal of Biotechnology

Volumn 27, Issue 5, 2011, Pages 717-723

  Diao, Yong ^a   Wang, Qizhao ^a   Xiao, Weidong ^a   Xu, Rui'an ^a  

^a HUAQIAO UNIVERSITY   (China)

Author keywords

Adeno associated virus; Gene therapy; Purification; Vector related impurity

Indexed keywords

CAPSID PROTEIN;

ADENO ASSOCIATED VIRUS; ARTICLE; GENE THERAPY; GENE VECTOR; GENETIC RECOMBINATION; GENETICS; ISOLATION AND PURIFICATION; METHODOLOGY; PHYSIOLOGY; VIRION; VIRUS ASSEMBLY; VIRUS REPLICATION;

CAPSID PROTEINS; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; RECOMBINATION, GENETIC; VIRION; VIRUS ASSEMBLY; VIRUS REPLICATION;

ADENO-ASSOCIATED VIRUS; PARVOVIRUS;

EID: 79961012660     PISSN: 10003061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Diao Y, Wang Q Z, Xiao W D, et al. Cellular immunotoxicity of rAAV gene medicine and possible solutions. Acta Pharm Sin, 2010, 45(9): 1071-1077.
2. Manno C S, Pierce G F, Arruda V R, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med, 2006, 12(3): 342-347.
3. + T-cell responses to adeno-associated virus capsid in humans. Nat Med, 2007, 13(4): 419-422.
4. Madsen D, Cantwell E R, O'Brien T, et al. Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1. J Gen Virol, 2009, 90(11): 2622-2633.
5. Wright J F. Transient transfection methods for clinical adeno-associated viral vector production. Hum Gene Ther, 2009, 20(7): 698-706.
6. Chadeuf G, Ciron C, Moullier P, et al. Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Mol Ther, 2005, 12(4): 744-753.
7. Li C W, Hirch M, Asokan A, et al. Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector transduced cells coexpressing the AAV2 capsid in vivo. J Virol, 2007, 81(14): 7540-7547.
8. Wang L L, Figueredo J, Calcedo R, et al. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T-cells but does not render hepatocytes effective cytolytic targets. Hum Gene Ther, 2007, 18(3): 185-194.
9. Wang X S, Khuntirat B, Qing K, et al. Characterization of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their elimination. J Virol, 1998, 72(7): 5472-5480.
10. Nony P, Chadeuf G, Tessier J, et al. Evidence for packaging of rep-cap sequences into adeno-associated virus (AAV) type 2 capsids in the absence of inverted terminal repeats: a model for generation of rep-positive AAV particles. J Virol, 2003, 77(1): 776-781.
11. Allen J M, Debelak D J, Reynolds T C, et al. Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production. J Virol, 1997,71(9): 6816-6822.
12. Cao L, Liu Y H, During M J, et al. High-titer, wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids. J Virol, 2000, 74(24): 11456-11463.
13. Hauck B, Murphy S L, Smith P H, et al. Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses. Mol Ther, 2009, 17(1): 144-152.
14. Cao L, During M, Xiao W. Replication competent helper functions for recombinant AAV vector generation. Gene Ther, 2002, 9(18): 1199-1206.
15. Mingozzi F, High K A. Immune responses to AAV in clinical trials. Curr Gene Ther, 2007, 7(5): 316-324.
16. Wright J F. Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther, 2008, 15(11): 840-848.
17. Auricchio A, Hildinger M, O'Connor E, et al. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther, 2001,12(1): 71-76.
18. Brument N, Morenweiser R, Blouin V, et al. A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5. Mol Ther, 2002, 6(5): 678-686.
19. Lock M, Alvira M, Vandenberghe L H, et al. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther, 2010, 21(10): 1259-1271.
20. Ayuso E, Mingozzi F, Montane J, et al. High AAV vector purity results in serotype-and tissue-independent enhancement of transduction efficiency. Gene Ther, 2010, 17(4): 503-510.
21. Qu G, Bahr-Davidson J, Prado J, et al. Separation of adeno-associated virus type 2 empty particles from genome-containing vector by anion-exchange column chromatography. J Virol Methods, 2007, 140(1/2): 183-192.
22. Okada T, Nonaka-Sarukawa M, Uchibori R, et al. Scalable purification of adeno-associated virus serotype 1 (AAV1) and AAV8 vectors, using dual ion-exchange adsorptive membranes. Hum Gene Ther, 2009, 20(9): 1013-1021.
23. Urabe M, Xin K Q, Obara Y, et al. Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression. Mol Ther, 2006, 13(4): 823-828.
24. Xie Q, Hare J, Turnigan J, et al. Large-scale production, purification and crystallization of wild-type adeno-associated virus-2. J Virol Methods, 2004, 122(1): 17-27.
25. Chahal P S, Aucoin M G, Kamen A. Primary recovery and chromatographic purification of adeno-associated virus type 2 produced by baculovirus/insect cell system. J Virol Methods, 2007, 139(1): 61-70.
26. Wright J F, Le T, Prado J, et al. Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. Mol Ther, 2005, 12(1): 171-178.
27. Croyle M A, Cheng X, Wilson J M. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther, 2001, 8(17): 1281-1290.
28. Bainbridge J W B, Ophth F R C, Smith A J, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med, 2008, 358(21): 2231-2239.
29. Maguire A M, Simonelli F, Pierce E A, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med, 2008, 358(21): 2240-2248.
30. Alberts B. The Breakthroughs of 2009.Science, 2009, 326(5960): 1589.
31. Xu R A, Xiao W D, Lu H. A HAAVmir gene containing a novel cell specific microRNA binding domain used for gene therapy: CN, 200910136134.5. 2009-09-16.
32. Lü Y, Wang Q, Xiao W D, et al. Trends in development of self-complementary adeno-associated virus vector. Chin J Biotech, 2009, 25(5): 658-664.
33. Wang F, Diao Y, Xiao W D, et al. Large-scale production of recombinant adeno-associated virus (rAAV). Chin J Biotech, 2009, 25(11): 1608-1613.